Antroquinonol (Hocena), an anti-cancer and anti-hyperlipidemia drug developed by a Taiwanese firm as a potential medicine to treat COVID-19, was approved by Peru's authorities to begin phase II trials, according to its developer.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Televised sessions planned ahead of nuclear plant restart referendum
07/03/2025 06:54 PM - Politics
Scholars split on prosecutor's nomination as head of top judicial body
07/03/2025 06:28 PM - Politics
- Business
Cabinet approves new incentives to attract investment in Taiwan
07/03/2025 05:32 PM - Science & Tech
Taiwanese team develops new treatment for triple-negative breast cancer
07/03/2025 05:23 PM